

# 9<sup>th</sup> Global Public Health, Occupational Safety and Health Policy March 23-24, 2023 | Webinar

Volume : 13

## Why Is Oral “Vaccine” for COVID-19 The Best Choice in This Pandemic?

### Huang Wei Ling

Medical Acupuncture and Pain Management Clinic., Brazil

**Introduction:** Since the end of 2019, the world begins to fight against the new SARS-CoV-2 infection, that caused until today 305 million infected people and 5,48 million deaths. There are increasing studies in how to prevent this infection using Pfizer, Moderna, Astra-Zeneca vaccines, etc but after months using these kinds of products worldwide, we still facing increasing cases of infections also in people who had received the vaccines and also the necessity of admitting them in the hospital. It was reported by CDC since 1900 until today (January 11th 2022), 14.317 deaths after receiving any kinds of vaccines and from these total, 10.688 deaths were following after these RNA-m of SARS-CoV-2 vaccines (0,0022%) and they are responsible for 74% of global deaths ( of the total of deaths after receiving vaccine) . Purpose; the purpose of this study is to show that injecting RNA-m vaccines for COVID-19 is not the only solution to control this pandemic and other forms of oral “vaccines” for COVID-19 can be used in this kind of situation without having so many side effects presented by the actual vaccines applied nowadays. Methods: this study will be based on the type of population that we have presently (that 90% is considered immunocompromised due to energy deficient state, in a research made by the author, caused by the influences of the electromagnetic waves that is affecting the whole world). In this case, we should use highly diluted “vaccines” to produce the result desired and not highly concentrated vaccines that the whole world is using nowadays. These thoughts were based on Arndt-Schultz Law, created in 1888 by two German researchers and they say that the use of highly concentrated medications can harm the vital energy, for this reason, this could be the fact of so many cases of thrombosis, myocardial infarction, strokes, auto-immune diseases or deaths after the COVID-19 vaccines injections applied in this new type of population. This study is based on the theory of Hahnemann (1755-1843), that said that you can treat the patient using the same substance that caused the disease but using it in an infinitesimal mode and for this reason, in Brazil, we are using secretions of patients that have SARS-CoV-2 infections and diluting them in an infinitesimal mode until PCR exam is negative to that sample. This type of oral “vaccine” can be used in any type of person with or without co-morbidities and can prevent or be used in the treatment of patient with acute infection of SARS-CoV-2 infection and it is the product of choice in prevention or treatment of patients with SARS-CoV-2 infection, due to the new pattern of energy presented by the majority of patients nowadays. Results: in our results, patients using these kinds of oral “vaccine” do not have SARS-CoV-2 infection that necessitate to be admitted in the hospital or die due to the use of this medication during this pandemic. When they have this infection using this kind of oral “vaccine”, they have only mild symptoms and only stayed at home without the necessity to be hospitalized.

### Biography

Huang Wei Ling, born in Taiwan, raised and graduated in medicine in Brazil, specialist in infectious and parasitic diseases, a General Practitioner and Parenteral and Enteral Medical Nutrition Therapist. Once in charge of the Hospital Infection Control Service of the City of Franca's General Hospital, she was responsible for the control of all prescribed antimicrobial medication and received an award for the best paper presented at the Brazilian Hospital Infection Control Congress in 1998. Since 1997, she works with the approach and treatment of all chronic diseases in a holistic way, with treatment guided through the teachings of Traditional Chinese Medicine and Hippocrates.

weilingmg@gmail.com

Abstract received : Feb 24, 2022 | Abstract accepted : Feb 25, 2022 | Abstract published : March 3, 2022